Modulation of terminally exhausted T cells by inhibiting molecules, such as PD-1, PD-L1 and CTLA-4, is the basis for ICI therapy, which has led to significant improvements in the survival of patients with advanced RCC. This evidence concerns the gene CD274 and renal cell carcinoma.